Substance P receptor antagonist reverses intestinal pathophysiological alterations occurring in a novel ex-vivo model of Cryptosporidium parvum infection of intestinal tissues derived from SIV-infected macaques

Journal of Medical Primatology

Volumn 37, Issue 3, 2008, Pages 109-115

  Garza, A ^a   Lackner, A ^b   Aye, P ^b   D'Souza, M ^a   Martin Jr , P ^a   Borda, J ^b   Tweardy, D J ^a   Weinstock, J ^c   Griffiths, J ^c   Robinson, P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

Cryptosporidiosis; Macaques; Substance P

Indexed keywords

AB 1566; APREPITANT; SUBSTANCE P; SUBSTANCE P ANTAGONIST;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; JEJUNUM; MACACA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; GENE EXPRESSION REGULATION; JEJUNUM; MACACA; RECEPTORS, NEUROKININ-1; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SUBSTANCE P; TISSUE CULTURE TECHNIQUES;

ANIMALIA; CRYPTOSPORIDIUM; CRYPTOSPORIDIUM PARVUM; MACACA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 44949152566     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2007.00251.x     Document Type: Article

References (21)

1. Abe Y, Bui-Thanh NA, Ballantyne CM, Burns AR: Extra domain A and type III connecting segment of fibronectin in assembly and cleavage. Biochem Biophys Res Commun 2005; 338: 1640-7.
2. Argenzio RA, Lecce J, Powell DW: Prostanoids inhibit intestinal NaCl absorption in experimental porcine cryptosporidiosis. Gastroenterology 1993; 104: 440-7.
3. Bernstein CN, Robert ME, Eysselein VE: Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 1993; 88: 908-13.
4. Derouin FG, Gangneux JP: Changing patterns of disease and treatment of opportunistic parasitic infections in patients with AIDS. Curr Opin Infect Dis 1998; 11: 711-6.
5. Genta RM, Chappell CL, White, AC. Jr, Kimball KT, Goodgame RW: Duodenal morphology and intensity of infection in AIDS-related intestinal cryptosporidiosis. Gastroenterology 1993; 105: 1769-75.
6. Goldin E, Karmeli F, Selinger Z, Rachmilewitz D: Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation. Dig Dis Sci 1989; 34: 754-7.
7. Goodgame RW, Kimball K, Ou CN, White AC. Jr, Genta RM, Lifschitz CH, Chappell CL: Intestinal function and injury in acquired immunodeficiency syndrome-related cryptosporidiosis. Gastroenterology 1995; 108: 1075-82.
8. Harp JA, Chen W, Harmsen AG: Resistance of severe combined immunodeficient mice to infection with Cryptosporidium parvum: The importance of intestinal microflora. Infect Immun 1992; 60: 3509-12.
9. Hernandez J, Lackner A, Aye P, Mukherjee K, Tweardy DJ, Mastrangelo MA, Joel W, Griffiths J, D'Souza M, Dixit S, Robinson P: Substance P is responsible for physiologic alterations such as increased chloride ion secretion and glucose-malabsorption in Cryptosporidiosis. Infect Immun 2007; 75: 1137-43.
10. Kandil HM, Berschneider HM, Argenzio RA: Tumour necrosis factor alpha changes porcine intestinal ion transport through a paracrine mechanism involving prostaglandins. Gut 1994; 35: 934-40.
11. Kapel N, Huneau JF, Magne D, Tome D, Gobert JG: Cryptosporidiosis-induced impairment of ion transport and Na + -glucose absorption in adult immunocompromised mice. J Infect Dis 1997; 176: 834-7.
12. Kelly P, Thillainayagam AV, Smithson J, Hunt JB, Forbes A, Gazzard BG, Farthing MJ: Jejunal water and electrolyte transport in human cryptosporidiosis. Dig Dis Sci 1996; 41: 2095-9.
13. Koch TR, Carney JA, Go VL: Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Dig Dis Sci 1987; 32: 369-76.
14. Lai JP, Douglas SD, Rappaport E, Wu JM, Ho WZ: Identification of a delta isoform of preprotachykinin mRNA in human mononuclear phagocytes and lymphocytes. J Neuroimmunol 1998; 91: 121-8.
15. Lambrecht BN, Germonpre PR, Everaert EG, Carro-Muino I, De Veerman M, de Felipe C, Hunt SP, Thielemans K, Joos GF, Pauwels RA: Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur J Immunol 1999; 29: 3815-25.
16. Lieb K, Treffurth Y, Berger M, Fiebich BL: Substance P and affective disorders: New treatment opportunities by neurokinin 1 receptor antagonists ? Neuropsychobiology 2002; 45: 2-6.
17. Mazumdar S, Das KM: Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am J Gastroenterol 1992; 87: 176-81.
18. Metwali A, Blum AM, Ferraris L, Klein JS, Fiocchi C, Weinstock JV: Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide. J Neuroimmunol 1994; 52: 69-78.
19. Riegler M, Castagliuolo I, So PT, Lotz M, Wang C, Wlk M, Sogukoglu T, Cosentini E, Bischof G, Hamilton G, Teleky B, Wenzl E, Mathews JL, Pothoulakis: Effects of substance P on human colonic mucosa in vitro. Am J Physiol 1999; 76: G1473-83.
20. Robinson P, Okhuysen PC, Chappell CL, Weinstock JV, Lewis DE, Actor JK, White AC. Jr: Substance P expression correlates with severity of diarrhea in cryptosporidiosis. J Infect Dis 2003; 188: 290-6.
21. Veazey RS, De Maria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, Rosenzweig M, Johnson RP, Desrosiers RC, Lackner AA: Gastrointestinal tract as a major site of CD4+T cell depletion and viral replication in SIV infection. Science 1998; 280: 427-31.